Black Diamond Therapeutics (BDTX) Competitors $2.72 +0.13 (+4.81%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BDTX vs. SAGE, UPXI, TRML, TERN, RAPP, BCYC, PGEN, OPT, SEPN, and ATYRShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Sage Therapeutics (SAGE), Upexi (UPXI), Tourmaline Bio (TRML), Terns Pharmaceuticals (TERN), Rapport Therapeutics (RAPP), Bicycle Therapeutics (BCYC), Precigen (PGEN), Opthea (OPT), Septerna (SEPN), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry. Black Diamond Therapeutics vs. Its Competitors Sage Therapeutics Upexi Tourmaline Bio Terns Pharmaceuticals Rapport Therapeutics Bicycle Therapeutics Precigen Opthea Septerna aTyr Pharma Black Diamond Therapeutics (NASDAQ:BDTX) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Do analysts rate BDTX or SAGE? Black Diamond Therapeutics currently has a consensus price target of $12.40, suggesting a potential upside of 355.05%. Sage Therapeutics has a consensus price target of $7.85, suggesting a potential downside of 9.56%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Sage Therapeutics 1 Sell rating(s) 13 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.93 Does the media refer more to BDTX or SAGE? In the previous week, Black Diamond Therapeutics had 5 more articles in the media than Sage Therapeutics. MarketBeat recorded 6 mentions for Black Diamond Therapeutics and 1 mentions for Sage Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.97 beat Sage Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sage Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in BDTX or SAGE? 95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 6.0% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, BDTX or SAGE? Black Diamond Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Is BDTX or SAGE more profitable? Black Diamond Therapeutics has a net margin of 0.00% compared to Sage Therapeutics' net margin of -427.78%. Black Diamond Therapeutics' return on equity of 12.70% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A 12.70% 9.58% Sage Therapeutics -427.78%-67.10%-58.42% Which has preferable valuation & earnings, BDTX or SAGE? Black Diamond Therapeutics has higher earnings, but lower revenue than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$69.68M$0.2311.85Sage Therapeutics$41.24M13.18-$400.67M-$4.89-1.78 SummaryBlack Diamond Therapeutics beats Sage Therapeutics on 14 of the 16 factors compared between the two stocks. Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.16M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio11.8520.4630.4325.11Price / SalesN/A237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book1.177.959.016.20Net Income-$69.68M-$54.72M$3.26B$265.38M7 Day Performance-2.33%1.56%1.00%-1.25%1 Month Performance-13.49%5.71%4.19%-0.81%1 Year Performance-58.27%9.01%28.39%18.83% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics3.3295 of 5 stars$2.73+4.8%$12.40+355.0%-54.8%$155.16MN/A11.8590SAGESage Therapeutics3.4054 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690UPXIUpexi2.7418 of 5 stars$5.62-7.0%$15.50+175.8%+89.4%$539.74M$26M0.00130Gap DownTRMLTourmaline Bio2.393 of 5 stars$20.99+1.3%$49.33+135.0%+56.6%$532.20MN/A0.0044Analyst RevisionTERNTerns Pharmaceuticals3.4933 of 5 stars$6.30+3.6%$15.63+148.0%-16.1%$532.07MN/A0.0040RAPPRapport Therapeutics1.706 of 5 stars$14.34-1.4%$29.50+105.7%-34.9%$531.04MN/A0.00N/AInsider TradeBCYCBicycle Therapeutics3.2184 of 5 stars$7.46-2.5%$24.00+221.7%-69.1%$529.79M$35.28M0.00240Short Interest ↓PGENPrecigen3.8662 of 5 stars$1.74-2.2%$6.00+244.8%+184.1%$525.42M$3.92M0.00190Trending NewsAnalyst ForecastOptions VolumeAnalyst RevisionOPTOpthea0.2602 of 5 stars$3.41+7.2%$1.33-60.9%+30.2%$524.84M$120K0.008News CoveragePositive NewsGap UpHigh Trading VolumeSEPNSepterna1.7698 of 5 stars$11.49-1.7%$26.75+132.8%N/A$520.89M$1.08M0.00N/ATrending NewsAnalyst ForecastAnalyst RevisionATYRaTyr Pharma2.177 of 5 stars$5.61+5.8%$20.20+260.1%+164.5%$519.33M$230K0.0053Short Interest ↑ Related Companies and Tools Related Companies SAGE Competitors UPXI Competitors TRML Competitors TERN Competitors RAPP Competitors BCYC Competitors PGEN Competitors OPT Competitors SEPN Competitors ATYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDTX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access